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Abstract
Although it was once thought that neurons solely rely on glucose as a substrate for
cellular energy production, it is now known that small monocarboxylate molecules, like
pyruvate, lactate, and ketone bodies, are also utilized. Monocarboxylates are transported across
plasma membranes via facilitated diffusion using a family of transport proteins known as
monocarboxylate transporters (MCTs). Four MCTs (MCT1, MCT2, MCT3, and MCT4) are
expressed within neural tissues. Expression of the MCTs has been tied to co-expression of a cell
adhesion molecule belonging to the Basigin subset of the immunoglobulin superfamily (IgSF).
Basigin gene products are known to interact with MCT1 and MCT4 in the mammalian neural
retina and this association is essential to support the cellular energy needs of photoreceptors. A
previous study indicated that Basigin gene products use hydrophobic amino acids within specific
regions of the transmembrane domain to interact with MCT1. In the present study, it is
hypothesized that the same amino acids within the transmembrane domain are used to interact
with MCT4, but that no association exists with MCT2, which typically interacts with a different
member of the IgSF subset. Therefore, the purpose of the present study was to assess the
association between Basigin gene products and MCT4, and with MCT2. Recombinant proteins
corresponding to the transmembrane domain of Basigin gene products were used in in vitro
binding assays with endogenous MCT2 and MCT4 from mouse brain protein lysates. Contrary
to the hypothesis, it was determined that the transmembrane domain of Basigin gene products
binds to both MCT2 and MCT4 in vitro. Different amino acids within the transmembrane
domain of Basigin gene products are used for each association and the pattern is different from
that used in the association with MCT1. The data suggest that Basigin plays multiple roles in the
nervous system.
ix

Chapter 1
Introduction
Cell adhesion is an essential process for the maintenance and development of tissues,
synaptogenesis, and embryonic development. Connections between cells, mediated by cellsurface proteins, underlie all these processes, and set up the three-dimensional structure of
tissues (Gumbiner, 1996). The proteins involved in cell adhesion can be classified into one of
four classes of cell adhesion molecules (Figure 1.1), which include the immunoglobulin
superfamily (IgSF), cadherins, selectins, and integrins (Alberts et al., 2015). Studies of the
expression, structure, and function of cell adhesion molecules are powerful ways to understand
the molecular composition of a tissue, and hence its function.

Immunoglobulin Super Family
The IgSF is the largest group of four types of cell adhesion molecules (Beesley et al.,
2014; Alberts et al., 2015). Members of the IgSF are typically characterized by a large aminoterminal extracellular domain containing one or more Ig folds, a single transmembrane domain,
and a cytoplasmic tail (Aplin et al., 1998). These Ig folds are similar in structure to those found
in immunoglobulins, or antibodies, and therefore provide the commonality for this group of
proteins (Alberts et al., 2015). IgSF cell adhesion molecules are involved in many processes and
found on many cell types, including the development of the nervous system, in which they are

Figure 1.1. The four classes of cell adhesion molecules. These include the immunoglobulin (Ig)
superfamily, cadherins, selectins, and integrins. (Alberts et al., 2000).
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used in the establishment and maintenance of neuronal connections and axonal guidance (Murase
and Schuman, 1999).

Cadherins
Cadherins are a family of transmembrane proteins that possess an extracellular domain
with a series of repeats of 100-amino acid cadherin-specific modules (Juliano, 2002). The
cadherin family of cell adhesion molecules can be divided into three major subfamilies. The first
subfamily is composed of primarily calcium-dependent homotypic cell adhesion molecules
referred to as “classic” cadherins. This subset of cadherins specializes in the formation of
adherence junctions with actin filaments (Angst et al., 2001). The second subfamily is composed
of desmosome-associated cell adhesion molecules. These cadherins form intracellular linkages
with intermediate filaments, rather than actin filaments (Hynes, 1999). The final subfamily of
cadherins are the proto-cadherins. These are important for the development of the nervous
system (Angst et al, 2001).

Selectins
The selectin family of cell adhesion molecules consist of a small family of lectin-like
adhesion receptors (Lasky, 1995). Lectins are carbohydrate-binding proteins (Aplin et al., 1998).
Selectins possess an amino-terminal domain homologous to calcium-dependent animal lectins,
an epidermal growth factor domain, two to nine complement regulatory protein repeats, a
transmembrane domain, and a short cytoplasmic tail (Juliano, 2002). Selectins regulate
heterotypic cell interactions via calcium-dependent recognition of sialylated glycans, which
3

plays a role in leukocyte adherence to endothelial cells and platelets during the inflammation
process (Springer, 1995).

Integrins
Integrins are cell-surface glycoproteins that serve as receptors for extracellular matrix
proteins and connect to the cytoskeleton, hence “integrating” the outside of the cell with the
inside of the cell (Juliano, 2002). Integrins exist as heterodimers consisting of two subunits,
known as α and β. The  and  subunits each contain an extracellular domain, a membrane
spanning region, and cytoplasmic domain (Hynes, 1999; Aplin et al., 1998). Signals originating
outside the cell are responsible for cytoskeletal organization, cell motility, and signal
transduction, whereas signals originating from inside the cell are responsible for regulation of
integrin affinity (Juliano, 2002).

Basigin subset of the IgSF
Within the IgSF exists a subset of proteins that includes two Basigin gene products, two
Neuroplastin gene products, and Embigin. These five proteins are classified as a subset of the
IgSF based on the similarities of these proteins at the amino acid level, and therefore their
structures (Beesley et al., 2014). As members of the IgSF, they share a similar structure, with
extracellular Ig-like domains, a transmembrane domain, and a cytoplasmic domain (Figure 1.2;
Beesley et al., 2014). A defining feature of this subset of the IgSF is the presence of a glutamate
residue within the transmembrane domain (Beesley et al., 2014). The function of this polar
amino acid within a hydrophobic domain of the protein has yet to be fully determined. The gene
4

Figure 1.2. Comparison of the structures of Neuroplastin, Basigin, and Embigin. Each protein
family possesses extracellular Ig domains, a transmembrane domain, and a cytoplasmic domain.
All members of this subset of the IgSF possess a glutamate (E) within the transmembrane domain.
There are two Basigin and Neuroplastin gene products. The longer product is depicted by the
additional lighter colored domain at the region most distal from the membrane. (Beesley et al.,
2014)
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for Basigin and the gene for Neuroplastin each produce two main protein products that differ in
overall size. The shorter forms of Basigin (Basigin variant-2) and Neuroplastin (Neuroplastin
gp55) are ubiquitously expressed and each have two extracellular Ig domains (Beesley et al.,
2014). The longer forms of Basigin (Basigin variant-1) and Neuroplastin (Neuroplastin gp65) are
expressed in the retina and the brain, respectively, and have three extracellular Ig domains each
(Figure 1.2; Beesley et al., 2014). The Embigin gene is unique to this subset, in that it codes for a
single polypeptide that has two extracellular Ig domains (Figure 1.2; Beesley et al., 2014).
Embigin is known as the “embryonic Ig,” based on early studies that indicated that expression is
highest during embryonic development (Fan et al., 1998). More recently, it has been determined
to be expressed during tissue regression of rat prostate and in mammary glands following
hormonal ablation (Guenette et al., 1997), as well as in adult rodent muscle (Lain et al., 2009).
As cell adhesion molecules, members of the Basigin subset of the IgSF play many roles
in many different tissues. Basigin variant-2 is known to be involved in glial cell maturation,
oocyte maturation, thymic development, and HIV-1 infection (Ding et al., 2002; Renno et al.,
2002; Pushkarsky et al., 2001). Conversely, Basigin variant-1 is expressed only in the neural
retina and is thought to play a role in regulation of glucose metabolism (Ochrietor et al., 2003;
Ait-Ali et al., 2015). The Neuroplastin gene products are specific to the brain and nervous
system and are important for mediating neurite outgrowth and plasticity, especially activitydependent synaptic plasticity (Beesley et al., 2014). Whereas Neuroplastin gp55 is expressed
throughout the mammalian brain, Neuroplastin gp65 expression is predominantly found in the
hippocampus, cortex, and striatum, with lower concentrations in the brainstem (Hill et al., 1988;
Mlinac et al., 2012.; Smalla et al., 2000; Marzban et al., 2003). Embigin regulates cell growth
and differentiation during embryonic development (Guenette et al., 1997). Embigin mRNA
6

levels are elevated in embryonic carcinoma cells, which supports the hypothesis that it is
involved in tumorigenesis and cancer development as well (Huang et al., 1990). The common
feature of the Basigin subset of the IgSF is their ability to associate with, and direct the
expression of, monocarboxylate transporters (Beesley et al., 2014).

Monocarboxylate Transporters
Monocarboxylate transporters (MCTs) are members of the MCT solute carrier family of
proteins. All family members possess a similar characteristic structure, consisting of twelve
transmembrane helices with intracellular carboxy- and amino-termini, as well as a large cytosolic
loop between transmembrane domains six and seven (Figure 1.3; Halestrap and Price, 1999).
There are nine different MCT isoforms, but only four of these (MCT1, MCT2, MCT3 and
MCT4) are known to transport pyruvate, lactate, and ketone bodies (monocarboxylates) via
facilitated diffusion, in a proton-dependent manner (Halestrap and Price, 1999). These isoforms
are known to interact with members of the Basigin subset of the IgSF and will therefore be the
focus of this discussion. However, because MCT3 is retina-specific (Philp et al., 2001), for this
discussion the focus will be on MCT1, MCT2, and MCT4. A comparison of the amino acid
sequences of MCT1, MCT2, and MCT4 is shown in Figure 1.4. The area designated by the box
shows transmembrane domain 3, which is thought to be the region within MCT1 that interacts
with Basigin (Manoharan et al., 2006).
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Figure 1.3. Structure of monocarboxylate transporters. The overall structure is depicted
using circles that represent each amino acid in the protein. The circles are color-coded to indicate
the class of amino acid present at each position. MCTs possess ten to twelve transmembrane
domains, with a large cytoplasmic domain between transmembrane domains six and seven. Both
the amino- and carboxy-termini are positioned within the cell. (Halestrap and Price, 1999)
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Figure 1.4. Amino acid sequence comparison of MCT1, MCT2, and MCT4. The one-letter amino
acid code is shown for each transporter. Positions that share identical amino acids are noted with
an asterisk (*), whereas positions that have conserved substitutions are noted with a colon (:) or a
period (.), depending on the strength of the conservation.

The boxed sequence shows

transmembrane domain 3, the region of MCT1 thought to interact with Basigin.
9

The MCT family members are expressed throughout the body. MCT1 is expressed in
many tissues and is thought to be responsible for basal monocarboxylate transport across
epithelial membranes (Halestrap, 2012). Within the brain, MCT1 and MCT2 expression has
been localized to the neocortex, hippocampus, cerebellum, and striatum (Pellerin et al., 1998). In
areas where MCT1 and MCT2 are both expressed, they are differentially localized, which may
be due to unique functional roles for each transporter (Halestrap, 2012). Expression of MCT2 is
largely found in the postsynaptic density of neurons and may therefore facilitate the uptake of
monocarboxylates for those cells (Halestrap, 2012). Conversely, expression of MCT1 is largely
found in the heart, brain, and retina (Bergersen, 2007; Halestrap and Price, 1999). MCT1 is
particularly expressed in the endothelial cells of capillaries in the brain (Bergersen, 2007). MCT4
is widely expressed in glycolytic tissues, such as white skeletal muscle fibers, astrocytes, white
blood cells, chondrocytes, and some mammalian cell lines. It is thought that MCT4 may be
involved in the export of lactic acid derived from glycolysis (Halestrap, 2012). While highly
glycolytic cells are shown to predominantly express and utilize MCT4, cells that have a net
influx of lactic acid express and utilize predominantly MCT1 (Kirk et al., 2000). MCT3 is
unique to this group in that its expression is restricted to the retinal pigmented epithelium (RPE)
of the eye (Philp et al., 2001). Excess lactate from the neural retina is moved into the RPE via
apically-expressed MCT1 and out of the RPE toward the choroid via basally-expressed MCT3
(Philp et al., 2001).
The mechanism by which MCTs transport monocarboxylates has been studied in detail
using inhibitors, transport kinetics, and site-directed mutagenesis (Halestrap, 2012). The MCT1
transporter has been the prototype molecule used for many of these studies. The mechanism
MCT1 utilizes is one in which a substrate binding site, open to one side of the membrane, binds a
10

proton and lactate anion, causing a conformational change in the protein which brings the two to
the opposite surface of the membrane (Halestrap, 2012). The MCT1 transporter specifically uses
a lysine residue in the hydrophobic pocket of the substrate-binding channel, that when coupled
with the binding of a proton, allows for the binding of the monocarboxylate anion (Halestrap,
2012).
While glucose is considered the main energy source for the brain, lactate and ketone
bodies can be utilized by neurons within the brain (Koehler-Stec et al., 1998). It has been
proposed that neurons obtain these metabolites to fuel oxidative phosphorylation using an
astrocyte-neuron coupling mechanism (Figure 1.5; Magistretti, 2006). It is thought that glucose
is taken up by astrocytes (glial cells), using the GLUT-1 transport protein (Magistretti, 2006),
and converted to pyruvate via glycolysis. The pyruvate is then reduced to lactate and shuttled to
neurons in close association with the astrocyte, which oxidize lactate to pyruvate and continue
the process of aerobic respiration (Magistretti, 2006). Lactate converted to ketone bodies within
the liver and released into the bloodstream can also be used by neurons, upon conversion of the
ketone bodies to pyruvate (Koehler-Stec et al., 1998). In addition, glucose directly enters the
neurons, via a separate mechanism, for glycolysis and aerobic respiration in those cells
(Magistretti, 2006). Not shown in the diagram are the MCTs that contribute to lactate transport
across the membranes of cells.
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Figure 1.5. The astrocyte-neuron coupling mechanism proposed to exist in the mammalian brain.
Glucose is taken up by astrocytes and metabolized to lactate, which is then delivered to neurons
and used as a substrate for cellular energy production. (Magistretti, 2006)
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The relationship between members of the Basigin subset of the IgSF and MCTs
Numerous studies conducted over the past two decades indicate that MCTs associate with
members of the Basigin subset of the IgSF. Basigin gene products are known to associate with
MCT1 and MCT4, as demonstrated via in vitro and in vivo analyses (Kirk et al., 2000; Wilson et
al., 2002; Philp et al., 2003; Finch et al., 2009). It has been proposed that expression of MCT1 is
dependent of its association with Basigin gene products, because absence of Basigin gene
expression in a mouse model system results in the absence of MCT1 protein at the plasma
membrane of the cell (Philp et al., 2003). The co-expression of Basigin and MCT1 correlates
with a substantially enhanced rate of lactate transport, as compared to cells not expressing both
proteins (Kirk et al., 2000). Similarly, a recent study suggests that Neuroplastin gene products
associate with MCT2 on neurons, although a direct relationship was not established (Wilson et
al., 2013). In another study, Embigin was co-expressed with MCT1 in erythrocytes (Wilson et
al., 2009). Although the study was limited by heterologous expression, rather than endogenous
expression, it did demonstrate that the two proteins interact at the plasma membrane (Wilson et
al., 2009).
The interaction between Basigin gene products and MCT1 has been studied at the
molecular level. Binding studies utilizing recombinant forms of the transmembrane domain of
Basigin gene products and endogenous mouse neural retina MCT1 demonstrated that this domain
of Basigin gene products does bind to MCT1 (Finch et al., 2009). Although it was hypothesized
that the central glutamate within the domain would play a significant role in binding to MCT1
(Wilson et al., 2002), it did not appear to play any role in the interaction (Finch et al., 2009). In
contrast, hydrophobic interactions were found to be responsible for the interaction with MCT1
(Figure 1.6; Finch et al., 2009).
13

Figure 1.6. The entire transmembrane domain of Basigin gene products (BasTM-All) is shown
using the amino acid one-letter code.

It was determined by Finch et al., (2009), that the

transmembrane domain of Basigin gene products (BasTM) binds to MCT1 using the hydrophobic
amino acids shown in blue. One letter code: A = alanine; E = glutamate; F = phenylalanine; G =
glycine; I = isoleucine; L = leucine; M = methionine; P = proline; T = threonine; V = valine; W =
tryptophan; Y = tyrosine
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In a study using a mouse model system, it was determined that Basigin gene expression
affects the expression of MCT1 and MCT4, but not MCT2 (Figure 1.7; Philp et al., 2003).
Immunoblotting analyses using detergent-solubilized protein lysates of the neural retinas from
Basigin null and control animals indicated that expression of MCT1 and MCT4 proteins was
significantly reduced at the plasma membrane of Basigin null animals, as compared to the
control animals (Figure 1.7; Philp et al., 2003). In contrast, the expression of MCT2 protein was
not different between the two groups (Figure 1.7; Philp et al., 2003). It is known that Basigin
gene products interact with MCT1 via the transmembrane domain (Finch et al., 2009).
Therefore, the purpose of the present study was to determine if Basigin gene products interact
with other members of the MCT family, specifically MCT2 and MCT4, using the same
mechanism. Based on previous data, it was hypothesized that Basigin gene products interact
with MCT4 in a similar manner to that of MCT1, whereas Basigin gene products do not interact
with MCT2 and thus it will serve as a negative control. This hypothesis was tested using a series
of biochemical analyses.

15

Figure 1.7. Basigin gene products affect the expression of MCT1 and MCT4, but not MCT2 in the
mouse neural retina. An immunoblot of neural retina membrane-associated protein expression is
shown. Samples from Basigin normal (Bsg +/+) and null (Bsg -/-) were tested from animals at 20days of age and one year of age. In the top panels, the proteins were probed with an antibody
specific for the glutamate transporter GLUT1, which served as a loading control. The remaining
panels show the results of probing with antibodies specific for MCT1, MCT4, and MCT2.
Expression of MCT1 and MCT4 is reduced in the null animals, as compared to the age-matched
normal animals, whereas the expression of MCT2 is similar for all samples. (Philp et al., 2003)
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Chapter 2
Materials and Methods
Recombinant protein expression and isolation
Expression plasmids containing the cDNA for the entire transmembrane domain of
Basigin gene products, as well as those containing truncated and mutated sequences were
previously generated (Finch et al., 2009; Brown, 2016). A plasmid containing no insert was also
previously generated and served as the control for binding assays (Finch et al., 2009). The
expression plasmid used was pET102 (Invitrogen Corporation, Carlsbad, CA), which allows
recombinant proteins containing an epitope of six histidine residues at the carboxy-terminus to
be expressed in bacteria. The plasmid codes for 157 amino acids, which mask the hydrophobic
nature of the Basigin-specific amino acids and allows a soluble protein to be expressed.
Recombinant protein expression was carried out by transforming BL21 cells (Invitrogen
Corporation). The cells were grown to mid-log phase, induced with 1 mM
isopropylthiogalactoside (IPTG; Thermo Fisher Scientific, Hampton, NH), and grown overnight
at 37oC with shaking.
Recombinant proteins were isolated using the His-TALON system (Clontech, Mountain
View, CA). Cells were pelleted by centrifugation at 3000 ×g for 15 minutes and resuspended in
X-tractor buffer (20 mL per 1 g of cells). The cells were lysed by incubation for 10 minutes at
room temperature in the presence of 100 g/mL lysozyme (Clontech) and 5 U/mL DNase I
(Clontech). A protein lysate was formed by centrifugation at 10,000 ×g for 20 minutes. The
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lysate was mixed with TALON purification resin (Clontech) for 10 minutes at room temperature.
The resin was washed by centrifugation and the via column gravity filtration. Proteins were
eluted from the column using elution buffer (Clontech) in 0.5 mL fractions and the presence of
protein was analyzed at 280 nm.

Mouse brain protein lysates
Three adult male mouse brains were obtained using an approved protocol and
immediately washed in phosphate buffered saline (PBS). Each brain was homogenized in
detergent lysis buffer (0.5% SDS, 0.05 M Tris⋅HCl, pH to 8.0, plus 1 mM fresh dithiothreitol
(DTT)) and incubated on ice for 10 minutes. A protein lysate was generated by centrifugation at
16,000 ×g for 10 minutes.

Bradford-Coomassie protein assay
Protein concentration of lysates was determined using the Bradford-Coomassie protein
assay method (Pierce/Thermo Scientific). Concentrations of bovine serum albumin (BSA,
Pierce/Thermo Scientific) ranging from 2.0 mg/mL to 0.1 mg/mL were generated and mixed
with Bradford-Coomassie binding reagent. The absorbance at 595 nm was measured and a
standard curve (absorbance versus protein concentration) was created. The equation from the
best-fit trendline (usually logarithmic) was used to determine the concentration of recombinant
and mouse brain protein samples.
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ELISA Binding Assay
Enzyme-linked immunosorbent assays (ELISA) were used as binding assays, as
described in Finch et al., (2009). Capture antibody (specific for MCT1, MCT2, or MCT4; 50
ng/mL in phosphate buffered saline [PBS]; Millipore Corporation, Billerica, MA) was plated and
incubated overnight at 4oC. The solution was removed, and the wells were washed with PBS
containing 0.25% Tween-20 (PBS-T). Bovine serum albumin (BSA; Pierce/Thermo Scientific),
diluted to 100 g/mL in PBS, was added to all wells and incubated at 37oC for 30 minutes. The
solution was removed, and wells were washed with PBS-T. Mouse brain protein lysates (100
g/mL) were added to all wells and incubated at 37oC for 30 minutes. The solution was
removed, and wells were washed with PBS-T. Recombinant proteins (diluted to 100 g/mL in
PBS) were added to individual wells in triplicate and incubated at 37oC for 30 minutes. The
solution was removed, and wells were washed with PBS-T. Primary antibody specific for the
carboxy-terminal six-histidine tag (diluted 1:1000 in PBS; BD Biosciences) was added to all
wells and incubated at 37oC for 30 minutes. The solution was removed, and wells were washed
with PBS-T. Alkaline phosphatase-conjugated goat anti-mouse secondary antibody (diluted
1:1000 in PBS) was added to all wells and incubated at 37oC for 30 minutes. The solution was
removed, and wells were washed with PBS-T. Alkaline phosphatase substrate (PNPP,
Pierce/Thermo Scientific) was added to all wells for color development. The reaction was
stopped with the addition of 2N NaOH. The absorbance at 405 nm was measured. All runs were
performed in triplicate, using different protein samples, and the average absorbance was plotted.
Binding was compared for Basigin-containing recombinant proteins with that of the control
recombinant protein via a paired, one-tailed T-test. For the binding assays that compared the
mutated sequence to the normal sequence, the average absorbance for the protein with the
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normal sequence was set to 100% binding and all mutant proteins were compared. Binding was
compared for mutant recombinant proteins with that of the normal recombinant protein via a
paired, one-tailed T-test.
Affinity binding assays were performed like the simple binding assays described, with
the exception that varying concentrations of recombinant protein (10 M, 5 M, 2.5 M, 1.25
M, 0.625 M) were used. All runs were performed in triplicate, using different brain protein
samples. The average absorbance for the protein at 10 M was set to 100% binding and the
absorbances for the other concentrations was compared. A binding curve was generated and the
equation for the logarithmic trendline was used to determine the concentration equal to 50%
binding. This was determined to be the binding affinity. The similarity of binding of Basigin
transmembrane domain recombinant protein for MCT1, MCT2, and MCT4 was compared via a
single factor ANOVA.

Immunohistochemistry
Many previous studies by this laboratory have involved the investigation of Basigin gene
expression in the retina. It was noted in a recent study in the lab that Basigin and MCT2
expression appears to overlap in tongue, thus providing a biologically relevant application for in
vitro data. Therefore, mouse tongues were isolated from adult male mice, according to an
accepted animal use protocol. The organs were washed in PBS and fixed by incubation for 24
hours in 4% paraformaldehyde in PBS at room temperature. The tissues were embedded in
paraffin wax and 5-m sections were cut and applied to poly-L-lysine-coated glass microscope
slides. The retina sections were previously generated (Ochrietor et al., 2003; Tokar et al., 2017).
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The tissue sections were rehydrated by incubating in CitriSolve (Fisher Scientific) twice,
for 10 minutes each time, followed by 5 minutes in 100% ethanol (Fisher Scientific), then 95%
ethanol, then 70% ethanol, and finally tris-buffered saline (TBS). The rehydrated sections were
solubilized in a buffer consisting of TBS with 0.1% Triton X-100 (Fisher Scientific) and 2%
normal goat serum (Pierce/Thermo Scientific) by incubation at 4oC overnight. The sections were
then incubated in the presence of an antibody specific for Basigin (Ochrietor et al., 2003) or
MCT2 (Millipore Corporation, Billerica, MA), diluted to 5 g/mL in the solubilization buffer for
1 hour at 37oC, followed by continued incubation at 4oC overnight. The solution was removed,
and the sections were washed several times with TBS. The sections were then incubated in the
presence of Alexa488-conjugated or Alexa594-conjugated goat anti-rabbit secondary antibody
(Pierce/Thermo Scientific) diluted 1:1000 in solubilization buffer and incubated at 37oC for 30
minutes. The solution was removed, and the sections were washed several times with TBS.
DRAQ5 (Pierce/Thermo Scientific) was added to the first TBS wash at 1:1000 dilution.
Coverslips were applied with 30% glycerol containing p-phenylenediamine (Sigma Chemical
Company, St. Louis, MO) and the tissues were viewed with an Olympus Fluoview F1000
confocal microscope (Pittsburgh, PA).
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Chapter 3
Results
Assessing the ability of Basigin to bind to MCT2 and MCT4
The purpose of the present study was to assess the ability of the transmembrane domain
of Basigin gene products to interact with MCT2 and MCT4. Previous studies indicate that
Basigin gene products interact with MCT1 using hydrophobic amino acids within the domain
(Finch et al., 2009). Other studies suggest that Basigin may interact with MCT4 using a similar
mechanism but does not likely interact with MCT2 (Philp et al., 2003). Therefore, the ability of
a recombinant form of the Basigin transmembrane domain to bind to endogenous mouse brain
MCT2 and MCT4 was tested.
Initially, simple ELISA binding assays were employed to test the ability of the
recombinant Basigin transmembrane domain protein to bind to endogenous mouse brain MCT2
and MCT4. The ability of the protein to bind to endogenous mouse brain MCT1 served as the
positive control. As observed previously, binding of the Basigin transmembrane domain protein
(BasTM-all) to MCT1 was significantly greater than the binding of the vector control protein
(control) to MCT1 (Figure 3.1A; p = 0.0009). Similarly, the ability of BasTM-all to bind to
MCT2 (Figure 3.1B; p = 0.009) and MCT4 (Figure 3.1C; p=0.001) was significantly greater than
binding of the control protein.
Next, the affinity of the transmembrane domain of Basigin gene products for MCT1,
MCT2, and MCT4 was assessed. Standard curves in which the recombinant BasTM-all protein
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Figure 3.1 Binding of Bas-TM-all to MCTs. The ability of Bas-TM-all to bind to MCT1 (A),
MCT2 (B), and MCT4 (C) was assessed via an in vitro binding assay. In all cases, the binding of
BasTM-all was significantly greater than that of the vector control protein (Control).
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was tested over a range of concentrations were used to determine the concentration at 50%
binding, which is considered the affinity. The affinity binding curves for BasTM-all against
MCT1, MCT2, and MCT4 are shown in Figure 3.2. Table 3.1 shows that the affinity of the
BasTM-all protein for each of the transporters. The affinities of BasTM-all for MCT1, MCT2,
and MCT4 were not significantly different from each other (p = 0.086).

Assessing the ability of the Basigin transmembrane domain to bind MCT2
To determine which amino acids within the transmembrane domain of Basigin gene
products are used in the interactions with MCT2, deletion mutants of the domain were used. The
domain was fractioned into six amino acid sections and the resulting recombinant proteins were
used for simple binding assays. It was determined that the region containing amino acids 1-6
had significantly greater binding to MCT2 than the control protein (p = 0.004) and similar to that
of the BasTM-all protein (p = 0.068; Figure 3.3). Conversely, the regions containing amino
acids 7-12 (p = 0.421) and 19-24 (p = 0.310) were not significantly greater than the control
protein (Figure 3.3). The ability of the region containing amino acids 13-18 was significantly
lower than that of the control protein (p = 0.003; Figure 3.3). To confirm the data obtained
through the simple binding assays, affinity assays were performed for each section of the Basigin
transmembrane domain (Table 3.2). The affinity for MCT2 of the region containing BasTM 1-6
(0.714±0.391 M) was significantly greater than that of the entire domain (BasTM-all; 1.70
±0.24 M; p = 0.041). The affinities for MCT2 of the regions contain BasTM 13-18 (2.82±0.22
M) and BasTM 19-24 (2.66±0.30 M) were significantly lower than that of BasTM-all (p =
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Figure 3.2 Binding curves for BasTM-6xHis with MCT1, MCT2, and MCT4. For each transporter,
the absorbance obtained for 10 M was set to 100% binding, and the other absorbances were
compared to it. A logarithmic trendline was applied and the equation was used to determine the
affinity. The R2 value for each trendline is shown.
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Table 3.1 Binding affinity of BasTM-6xHis for MCT1, MCT2, and MCT4 in µM.

Transporter Binding affinity (M)
MCT-1
MCT-2
MCT-4

1.74 +/- 0.12
1.70 +/- 0.24
1.36 +/- 0.19
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Figure 3.3 Binding of BasTM truncation mutants to MCT2. The ability of each section of the
transmembrane domain of Basigin (BasTM 1-6, BasTM 7-12, BasTM 13-18, BasTM 19-24) to
bind to MCT2 was assessed through an in vitro binding assay. The binding of each BasTM protein
was individually compared to that of the control protein using a paired, one-tailed T-test. The
asterisk (*) represents p=<0.01.
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Table 3.2 Binding affinity of BasTM-all and the Bas-TM truncation mutants for MCT2 in M.
The p-value was obtained via a paired, one-tailed T-test comparing each mutant to the BasTMall protein.

Protein

Affinity

BasTM-all

1.70 ±0.24 M

BasTM 1-6

0.714±0.391 M

0.041

BasTM 7-12

1.70±0.88 M

0.492

BasTM 13-18

2.82±0.22 M

0.019

BasTM 19-24

2.66±0.30 M

0.045

BasTM-all-E13G 1.43±0.266 M
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p-value

0.187

0.019, p = 0.045, respectively). Contrary to the data obtained from the simple binding assay, the
affinity for MCT2 of the region containing BasTM 7-12 (1.70±0.88 M) was the same as that for
BasTM-all. These data suggest that binding of the transmembrane domain of Basigin to MCT2
employs amino acids within the first twelve residues of the domain.
The glutamate residue found in the center of the transmembrane domain of Basigin, at
position 13, has been hypothesized by others to be essential for the interaction with MCTs (Kirk
et al., 2000; Wilson et al., 2002). Although the affinity data generated through this study suggest
otherwise, a direct assessment of the residue was performed using a recombinant version of the
entire Basigin transmembrane domain, in which the amino acid glutamate was mutated to
glycine (BasTM-all-E13G), and in an affinity binding assay (Figure 3.4). The affinity of the
BasTM-all-E13G protein for MCT2 was determined to be 1.429 ± 0.266 M, which is not
statistically different from the affinity of the wild-type sequence for the transporter when
compared using a paired, one-tailed T-test (p = 0.187; Table 3.2). These data suggest that the
glutamate plays no role in the interaction between Basigin and MCT2.
To determine which amino acids in the segment containing amino acids 1-6 are used in
the interaction with MCT2, deletion mutants in which individual amino acids were mutated to
glycine were used. Binding of each mutant was compared to that of the BasTM 1-6 protein
(Figure 3.5). It was determined that the proteins containing an alanine-to-glycine mutation at
position 3 (p = 0.001) and a leucine-to-glycine at position 4 (p = 0.01) had significantly lower
binding to MCT2 than the BasTM 1-6 protein. These amino acids are likely used in the
association with MCT2. The proteins containing a methionine-to-glycine mutation at position 1
(p = 0.001), an alanine-to-glycine mutation at position 2 (p = 0.048), and a tryptophan-to-glycine
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Figure 3.4 Binding curve of BasTM-all-E13G for MCT2. The absorbance obtained for 10 M
was set to 100% binding, and the other absorbances were compared to it. A logarithmic trendline
was applied and the equation was used to determine the affinity. The R2 value for the trendline is
shown.
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Figure 3.5 Binding of BasTM 1-6 mutants to MCT2. The ability of each amino acid to contribute
to binding to MCT2 was evaluated through an in vitro binding assay, and compared to that of the
BasTM 1-6 sequence, which was set to 100% binding. Mutants with binding greater than 100%
are thought to inhibit the interaction with MCT2, whereas those with binding less than 100% are
thought to be involved in the interaction. *=p<0.05 when individually compared to BasTM 1-6
via a paired, one-tailed T-test.
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mutation at position 5 (p = 0.05) had significantly greater binding to MCT2 than the BasTM 1-6
protein. These amino acids likely inhibit the interaction with MCT2.
To determine which amino acids in the segment containing amino acids 7-12 are used in
the interaction with MCT2, deletion mutants in which individual amino acids were mutated to
glycine were used. Binding of each mutant was compared to that of the BasTM 7-12 protein
(Figure 3.6). It was determined that mutation of no amino acids resulted in a significant decrease
in binding. On the contrary, mutation of the phenylalanine at position 7 (p=0.003), the leucine at
position 8 (p=0.006), the isoleucine at position 10 (p=0.031), and the alanine at position 12
(p=0.009) had significantly greater binding to MCT2 than BasTM 7-12. Mutation of the valine
at position 11 had similar binding to MCT2 as BasTM 7-12 (p=0.247). The amino acid at
position 9 is glycine and therefore was not mutated.

Assessing the ability of the Basigin transmembrane domain to bind MCT4
To determine which amino acids within the transmembrane domain of Basigin gene
products are used in the interactions with MCT4, deletion mutants of the domain were again
used. It was determined that the regions containing amino acids 1-6 and 7-12 had significantly
greater binding to MCT4 than the control protein (p = 0.018, 0.024, respectively; Figure 3.7) and
similar to that of the BasTM-all protein (p = 0.099, 0.250, respectively), whereas the region
containing amino acids 19-24 was not greater than the control protein (p = 0.255; Figure 3.7).
The ability of the region containing amino acids 13-18 was significantly lower than that of the
control protein (p = 0.002; Figure 3.7). To confirm the data obtained through the simple binding
assays, affinity assays were performed for each section of the Basigin transmembrane domain
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Figure 3.6 Binding of BasTM 7-12 mutants to MCT2. The ability of each amino acid to contribute
to binding to MCT2 was evaluated through an in vitro binding assay, and compared to that of the
BasTM 7-12 sequence, which was set to 100% binding. Mutants with binding greater than 100%
are thought to inhibit the interaction with MCT2, whereas those with binding less than 100% are
thought to be involved in the interaction. *=p<0.05 when individually compared to BasTM 7-12
using a paired, one-tailed T-test.
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Figure 3.7 Binding of BasTM truncation mutants to MCT4. The ability of each section of the
transmembrane domain of Basigin (BasTM 1-6, BasTM 7-12, BasTM 13-18, BasTM 19-24) to
bind to MCT4 was assessed through an in vitro binding assay. The binding of each BasTM mutant
protein was individually compared to that of the BasTM-all protein using a paired, one-tailed Ttest. The asterisk (*) represents p=<0.01.
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Table 3.3 Binding affinity of BasTM-all and the Bas-TM truncation mutants for MCT4 in M.
The p-value was obtained via a paired, one-tailed T-test comparing each mutant to the BasTMall protein.

Protein

Affinity

BasTM-all

1.36±0.19 M

BasTM 1-6

1.76±0.433 M

0.185

BasTM 7-12

2.03±0.14 M

0.015

BasTM 13-18

0.838±0.280 M

0.032

BasTM 19-24

2.44±0.12 M

0.012

BasTM-all-E13G 1.69±0.127 M
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p-value

0.043

(Table 3.3). The affinity for MCT4 of the region containing BasTM 1-6 (1.76±0.433 M) was
similar to that of the entire domain (BasTM-all; 1.36 ±0.19 M). The affinities for MCT4 of the
regions containing BasTM 7-12 (2.03±0.14 M) and BasTM 19-24 (2.44±0.12 M) were
significantly lower than that of BasTM-all. Surprisingly, the affinity for MCT4 of the region
containing BasTM 13-18 was significantly greater than that of BasTM-all (0.838±0.280; p =
0.032). These data suggest that amino acids within the first six residues of the domain may play
a role in binding to MCT4, but amino acids within residues 13-18 play a more significant role in
the interaction. The glutamate residue within the transmembrane domain of Basigin gene
products is found at position 13. The role of this amino acid was tested using the recombinant
version of the entire Basigin transmembrane domain, in which the amino acid glutamate was
mutated to glycine (BasTM-all-E13G), in an affinity binding assay (Figure 3.8). The affinity of
the BasTM-all-E13G protein for MCT4 was determined to be 1.69 ± 0.127 M, which is
statistically greater than the affinity of the wild-type sequence for the transporter (p = 0.043;
Table 3.3). These data suggest that the glutamate plays a direct role in the interaction between
Basigin and MCT4.
To determine which amino acids in the segment containing amino acids 1-6 are used in
the interaction with MCT4, deletion mutants in which individual amino acids were mutated to
glycine were used. Binding of each mutant was compared to that of the BasTM 1-6 protein
(Figure 3.9). It was determined that the protein containing an alanine-to-glycine mutation at
position 3 (p = 0.046) had significantly lower binding to MCT4 than the BasTM 1-6 protein.
This amino acid likely binds to MCT4. The proteins containing a methionine-to-glycine
mutation at position 1 (p = 0.009), an alanine-to-glycine mutation at position 2 (p = 0.041), a
tryptophan-to-glycine mutation at position 5 (p = 0.023), and a proline-to-glycine mutation at
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Figure 3.8 Binding curve of BasTM-all-E13G for MCT4. The absorbance obtained for 10 M was
set to 100% binding, and the other absorbances were compared to it. A logarithmic trendline was
applied and the equation was used to determine the affinity. The R2 value for the trendline is
shown.
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Figure 3.9 Binding of BasTM 1-6 mutants to MCT4. The ability of each amino acid to contribute
to binding to MCT4 was evaluated through an in vitro binding assay, and compared to that of the
BasTM 1-6 sequence, which was set to 100% binding. Mutants with binding greater than 100%
are thought to inhibit the interaction with MCT4, whereas those with binding less than 100% are
thought to be involved in the interaction. *=p<0.05 when individually compared to BasTM 1-6
using a paired, one-tailed T-test.

38

position 6 (p = 0.008) had significantly greater binding to MCT4 than the BasTM 1-6 protein.
These amino acids are likely inhibitory in the interaction with MCT4.
To determine which amino acids in the segment containing amino acids 13-18 are used in
the interaction with MCT4, deletion mutants in which individual amino acids were mutated to
glycine were again used. Binding of each mutant was compared to that of the BasTM 13-18
protein (Figure 3.10). It was determined that the protein containing a glutamate-to-glycine
mutation at position 13 (p = 0.022) had significantly lower binding to MCT4 than the BasTM 1318 protein. This amino acid likely binds to MCT4. The proteins containing a leucine-to-glycine
mutation at position 15 (p = 0.010), a valine-to-glycine mutation at position 16 (p = 0.002), a
leucine-to-glycine mutation at position 17 (p = 0.002), and a valine-to-glycine mutation at
position 18 (p = 0.004) had significantly greater binding to MCT4 than the BasTM 13-18
protein. These amino acids are likely inhibitory in the interaction with MCT4.

Assessing the expression of Basigin and MCT2 in vivo
To assess the biological relevance of the ability of Basigin to bind to MCT2,
immunohistochemical analyses were conducted. Paraffin-embedded sections of mouse retina
were subjected to immunohistochemical analyses using antibodies specific for Basigin and
MCT2 (Figure 3.11). While Basigin is found on the Muller cells, photoreceptor cells, and blood
vessels of the retina, MCT2 expression predominates in the inner and outer plexiform layers,
where synapses between neurons form. A more recent study by this laboratory investigated the
expression of Basigin gene products within the mouse tongue (Figure 3.12). Basigin and MCT2
overlap in the taste buds on the surface of the tongue epithelium.
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Figure 3.10 Binding of BasTM 13-18 mutants to MCT4. The ability of each amino acid to
contribute to binding to MCT4 was evaluated through an in vitro binding assay, and compared to
that of the BasTM 13-18 sequence, which was set to 100% binding. Mutants with binding greater
than 100% are thought to inhibit the interaction with MCT4, whereas those with binding less than
100% are thought to be involved in the interaction. *=p<0.05 when individually compared to
BasTM 13-18 using a paired, one-tailed T-test.
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Figure 3.11. Expression of Basigin and MCT2 in the mouse retina. In both panels, the green
fluorescence represents protein expression (Basigin or MCT2) and the blue fluorescence
represents DRAQ5, which binds DNA. The magnification bar represents 50 m. Abbreviations:
RPE, retinal pigmented epithelium; ONL, outer nuclear layer; OPL, outer plexiform layer; INL,
inner nuclear layer; IPL, inner plexiform layer.
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Figure 3.12 Expression of Basigin and MCT2 in mouse tongue. In the left panel, Basigin
expression is represented by red fluorescence. In the right panel, MCT2 expression is
represented by green fluorescence. In both panels, DRAQ 5 binding to DNA is represented by
the blue fluorescence. The magnification bars represent 50 m.
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Chapter 4
Discussion
It is generally accepted that the proton-linked monocarboxylate transporters MCT1,
MCT2, and MCT4 require an interaction with a cell adhesion molecule of the Basigin subset of
the IgSF for expression at the plasma membrane and transport as an accessory protein to express
at the plasma membrane (Kirk et al., 2000; Philp et al., 2003; Wilson et al., 2009). It was
thought that Basigin gene products interact with MCT1 and MCT4 (Kirk et al., 2000; Philp et al.,
2003), whereas the Neuroplastins interact with MCT2 (Wilson et al., 2013). Little is known of
Embigin, but it was shown to interact with MCT1 (Wilson et al., 2009). The purpose of the
present study was to characterize the interaction between Basigin gene products and MCT4, to
determine if that interaction is like that for MCT1. During the investigation, it was determined
that the interactions of Basigin gene products with MCT1 and MCT4 are quite distinct from each
other. Additionally, although it was designed to serve as a negative control, an interaction
between Basigin gene products and MCT2 was identified. That interaction differs from those of
the other two transporters. In all, the data suggest that Basigin gene products, especially Basigin
variant-1, which is ubiquitously expressed, are highly versatile proteins.
While simple binding studies are useful in establishing interactions between proteins,
affinity binding assays allow the interaction to be quantified and compared. Initially,
interactions between the transmembrane domain of Basigin and MCT1 were used as a positive
control and to validate the study system used. Affinity data for the Basigin-MCT1 interaction
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obtained through this study was similar to those of previous studies and suggest that the
interaction is of moderate affinity (Howard et al., 2010). This study demonstrated that the
affinity of Basigin for MCT2 and for MCT4 were statistically similar to that of MCT1. This is
the first study to indicate that Basigin can interact with MCT2, which was previously thought to
interact solely with the Neuroplastins (Beesley et al., 2014). The moderate affinity for MCT4 is
not surprising considering a recent study in which an interaction between Basigin and MCT4 was
determined to be crucial for development of glioblastoma and disruption of that interaction can
reverse that development (Voss et al., 2017).
The interactions between Basigin and monocarboxylate transporters are distinct. A
previous study in which the interaction between the transmembrane domain of Basigin gene
products and MCT1 was investigated indicated that hydrophobic amino acids on both “ends” of
the domain were used (Finch et al., 2009). In the present study, it was determined that the
interaction between Basigin and MCT2 utilizes two of the three amino acids at the extracellularfacing portion of the membrane-spanning domain that are used by MCT1. However, no amino
acids within the cytoplasmic-facing portion of the membrane-spanning domain are used. In
contrast, it was determined that for the interaction with MCT4, Basigin uses only one amino acid
within the extracellular-facing portion of the membrane-spanning domain used for the
interactions with MCT1 and MCT2, but also uses the glutamate residue positioned at the center
of the domain. A summary of the interactions is shown in Figure 4.1.
One exciting component of the present study was the finding that the glutamate residue
within the transmembrane domain of Basigin is used in the interaction with MCT4. In previous
studies of Basigin and MCT1, it was hypothesized that the polar, charged amino acid glutamate
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Figure 4.1. Summary of Basigin binding to monocarboxylate transporters. The transmembrane
domain is depicted with the one-letter code for the individual amino acids shown in the circles.
Amino acids within white circles are not used to bind any MCT. Amino acids within blue circles
are used by MCT1 only. Amino acids within red circles are used by MCT4 only. Amino acids
within green circles are used by MCT1 and MCT2. Amino acids within yellow circles are used
by MCT1, MCT2, and MCT4.
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must have a specific function within the hydrophobic domain of Basigin, and that the function
was for the purposes of chaperoning MCT1 to the cell surface (Kirk et al., 2000). That
hypothesis was not supported by data from a previous study by this laboratory (Finch et al.,
2009). However, the role of the glutamate was never determined. In the present study, it was
determined through two independent assays that glutamate interacts with MCT4. When the
residue was mutated to glycine within a recombinant protein consisting of the entire BasTM
domain (BasTM-E13G), the affinity of the protein for MCT4 was statistically lower than that of
the original BasTM protein. In addition, the simple binding assay using deletion mutants
consisting of BasTM 13-18 showed that mutation of glutamate to glycine produced significantly
decreased binding to MCT4 when compared to the original BasTM 13-18 sequence. A recent
study using glioblastoma stem cells indicated that the interaction between Basigin and MCT4
can be disrupted by acriflavine (Voss et al., 2017). The acriflavine molecule binds to the
extracellular domain of Basigin, as determined by surface plasmon resonance, and can prohibit
proliferation of the glioblastoma cells (Voss et al., 2017). Even more impressively, disruption of
the Basigin-MCT4 interaction in mice with glioblastoma xenographs, showed significant
inhibition of tumor progression in both early and late stages of the disease (Voss et al., 2017).
The data presented herein suggest that the interaction between acriflavine and Basigin creates
either a conformational change in the Basigin molecule that prevents the glutamate from
interacting with MCT4 or changes the charge on the glutamate residue within Basigin and hence
prevents an interaction with MCT4.
Another exciting finding from this study is the fact that Basigin binds to MCT2. Previous
studies in which the expression of MCTs in the absence of Basigin gene expression was
investigated indicated that expression of MCT1 and MCT4 were altered in the absence of
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Basigin, whereas the expression of MCT2 was unaffected (Philp et al., 2003). The
immunohistochemical analyses presented in this study provide an explanation for that
observation. Basigin and MCT2 are not expressed in the same places within the retina.
Therefore, Basigin does not affect MCT2 expression in that tissue. The immunohistochemical
analyses of mouse tongue suggest that Basigin and MCT2 expression do overlap in that organ
and provide biological relevance to the biochemical data obtained. Unfortunately, an analysis of
MCT2 expression in the mouse tongue in the absence of Basigin expression is beyond the
current abilities of the laboratory and cannot be undertaken. The laboratory has not been able to
produce a Basigin-null animal in several years.
In conclusion, it has been demonstrated that the transmembrane domain of Basigin can
interact with MCT1, MCT2, and MCT4. The amino acids used in the interactions differs by
transporter. The observed preference of Basigin for MCT1 and MCT4 is therefore more likely
an effect of overlapping expression, rather than the ability to interact.
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